Menu
News
Immunyx selected as a Quick Fire Challenge Project Nextgen Recipient
September 2023
The Biomedical Advanced Research and Development Authority (BARDA) and Johnson & Johnson Innovation are thrilled to announce...
Immunyx selected as a BlueKnight Company
January 2023
Immunyx Pharma, a developer of immune modulating therapies for neutrophil based diseases, announced it has been selected...
Targeted nanoparticles modify neutrophil function in vivo
October 2022
Neutrophils play critical roles in a broad spectrum of clinical conditions. Accordingly, manipulation of neutrophil...
